VTYX

1.77

5.35% -0.10

Dopo l'orario di chiusura: 1.77

Ventyx Biosciences Inc (VTYX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché VTYX Giù? Forum Previsione

Precedente Chiudi:

$1.87

Aprire:

$1.9

Volume 24 ore:

2.87M

Relative Volume:

2.43

Capitalizzazione di mercato:

$129.40M

Reddito:

Utile/perdita netta:

$-192.96M

Rapporto P/E:

-0.6321

EPS:

-2.8

Flusso di cassa netto:

$-167.04M

1 W Prestazione:

-17.67%

1M Prestazione:

-30.31%

6M Prestazione:

-62.58%

1 anno Prestazione:

-28.34%

Intervallo 1D:

$1.75

$1.905

Intervallo di 1 settimana:

$1.75

$2.21

Portata 52W:

$1.75

$11.48

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Nome

Ventyx Biosciences Inc

Settore

Healthcare (1196)

Industria

Biotechnology (683)

Telefono

(858) 945-2393

Indirizzo

12790 EL CAMINO REAL, SUITE 200, SAN DIEGO

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

VTYX's Discussions on Twitter

Confronta VTYX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTYX	1.77	129.40M	0	-192.96M	-167.04M	-2.80
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-03-21	Iniziato	Wells Fargo	Overweight
2022-12-19	Iniziato	Goldman	Buy
2022-11-17	Iniziato	Morgan Stanley	Overweight
2022-09-07	Iniziato	Stifel	Buy
2022-09-01	Iniziato	H.C. Wainwright	Buy
2022-05-09	Iniziato	Credit Suisse	Outperform
2022-03-31	Iniziato	Canaccord Genuity	Buy
2022-02-01	Iniziato	Oppenheimer	Outperform
2021-11-15	Iniziato	Jefferies	Buy
2021-11-15	Iniziato	Piper Sandler	Overweight

Mostra tutto

Ventyx Biosciences Inc Borsa (VTYX) Ultime notizie

Nov 17, 2024

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance

Nov 17, 2024

Nov 14, 2024

We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully - Simply Wall St

Nov 14, 2024

Nov 12, 2024

Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress - Yahoo Finance

Nov 12, 2024

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - The Manila Times

Nov 12, 2024

Nov 11, 2024

Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024

Ventyx Biosciences’ (VTYX) “Outperform” Rating Reiterated at Oppenheimer - Defense World

Nov 11, 2024

Nov 08, 2024

Ventyx Biosciences (NASDAQ:VTYX) Given "Outperform" Rating at Oppenheimer - MarketBeat

Nov 08, 2024

Nov 07, 2024

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress - The Manila Times

Nov 07, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com

Nov 05, 2024

Nov 04, 2024

Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha

Nov 04, 2024

Nov 01, 2024

Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com

Nov 01, 2024

Oct 28, 2024

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider

Oct 28, 2024

Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat

Oct 28, 2024

Oct 17, 2024

HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat

Oct 17, 2024

Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com

Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com

Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK

Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire

Oct 16, 2024

Oct 15, 2024

Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat

Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com

Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada

Oct 15, 2024

VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Oct 15, 2024